Idiopathic Pulmonary Fibrosis clinical trials

Explore recruiting idiopathic pulmonary fibrosis clinical trials.

Recruiting idiopathic pulmonary fibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Idiopathic Pulmonary Fibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW)

Germany, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-armed, phase II clinical multicentre randomized, placebo-controlled (2:1), blinded with open-label extension trial (TEFIBEOS)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Pragmatic management of progressive disease in idiopathic pulmonary fibrosis: a randomized trial. PROGRESSION-IPF

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibrosis (WHISTLE-PF Trial)

Belgium, Ireland, Germany, Italy, Austria, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

Greece, France, Netherlands, Italy, Spain, Czechia +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)

Germany, Netherlands, Italy, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Idiopathic Pulmonary Fibrosis trials by city

Idiopathic Pulmonary Fibrosis in Toronto Idiopathic Pulmonary Fibrosis in Vancouver Idiopathic Pulmonary Fibrosis in Montreal Idiopathic Pulmonary Fibrosis in Calgary Idiopathic Pulmonary Fibrosis in Edmonton Idiopathic Pulmonary Fibrosis in Ottawa Idiopathic Pulmonary Fibrosis in Winnipeg Idiopathic Pulmonary Fibrosis in Quebec City Idiopathic Pulmonary Fibrosis in Hamilton Idiopathic Pulmonary Fibrosis in Kitchener Idiopathic Pulmonary Fibrosis in London Idiopathic Pulmonary Fibrosis in Halifax Idiopathic Pulmonary Fibrosis in New York Idiopathic Pulmonary Fibrosis in Los Angeles Idiopathic Pulmonary Fibrosis in Chicago Idiopathic Pulmonary Fibrosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease